Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.

By M. Weir, G. Bakris, D. Bushinsky, M. Mayo, D. Garza, Y. Stasiv, J. Wittes, H. Christ-schmidt, L. Berman, B. Pitt. New England Journal of Medicine, 2015

612 citations recorded by the source corpus.

Subfields: Nutrition and Dietetics, Pharmacology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/691d0913e0cc89b0b62fe3bbb6729790176532dc

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. P. Ponikowski
2. A. Voors
3. V. Harjola
4. J. Parissis
5. M. Jessup
6. B. Pieske
7. E. Jankowska
8. Héctor Bueno

Citations in the corpus

• 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (2016, positive): “Two new potassium binders (patiromer and sodium zirconium cyclosilicate) are currently under consideration for regulatory approval.(453,454) Initial results from patients with HF are available and confirm the efficacy of these therapies in reducing serum potassium(455) and preventing recurrent hyper”